Market News

Reasons for Thomas Wilson’s Share Acquisition of Jack Henry & Associates, Inc. (JKHY)’s Stock; Flexion Therapeutics (FLXN) Shorts Increased By 0.18%

Henry Jack & Associates Inc director Thomas Wilson on the February 16, 2018 obtained a total of 1,000 shares of the corporation with market value of about $119,398 USD. This is exactly based on the average stock price value of $119.4 USD. The dated February 16, 2018 transaction’s filing filed with the Security and Exchange Commission is freely available here. This trade decreased his ownership of Henry Jack & Associates Inc to 0.02% total market cap or 18,866 shares.

Flexion Therapeutics Incorporated (NASDAQ:FLXN) had an increase of 0.18% in short interest. FLXN’s SI was 10.37M shares in February as released by FINRA. Its up 0.18% from 10.35M shares previously. With 1.20M avg volume, 9 days are for Flexion Therapeutics Incorporated (NASDAQ:FLXN)’s short sellers to cover FLXN’s short positions. The SI to Flexion Therapeutics Incorporated’s float is 42.63%. The stock decreased 5.66% or $1.39 during the last trading session, reaching $23.19. About 633,162 shares traded. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has risen 82.02% since February 17, 2017 and is uptrending. It has outperformed by 65.32% the S&P500.

Investors sentiment decreased to 1.03 in Q3 2017. Its down 0.28, from 1.31 in 2017Q2. It fall, as 23 investors sold Jack Henry & Associates, Inc. shares while 133 reduced holdings. 46 funds opened positions while 115 raised stakes. 66.01 million shares or 3.59% less from 68.47 million shares in 2017Q2 were reported. Brown Brothers Harriman & reported 217 shares. Fincl Bank Of New York Mellon Corporation owns 0.04% invested in Jack Henry & Associates, Inc. (NASDAQ:JKHY) for 1.25M shares. Welch & Forbes Limited Liability Corp accumulated 4,725 shares or 0.01% of the stock. Duncker Streett & Communication, Missouri-based fund reported 342 shares. Mitsubishi Ufj Trust And Corporation reported 0.04% of its portfolio in Jack Henry & Associates, Inc. (NASDAQ:JKHY). 9,961 are held by Mai Capital Management. 6,900 are owned by Hikari Tsushin. Geode Capital Management Limited Liability Company reported 821,901 shares or 0.03% of all its holdings. Wendell David reported 26,470 shares. Ajo Lp invested in 13,800 shares. The Kansas-based Retirement Planning Gru has invested 0.15% in Jack Henry & Associates, Inc. (NASDAQ:JKHY). Intrust Financial Bank Na accumulated 3,312 shares. Dupont Capital Management Corp accumulated 23,001 shares or 0.05% of the stock. Laurion Capital Management Limited Partnership invested 0.01% in Jack Henry & Associates, Inc. (NASDAQ:JKHY). Arrowstreet Cap Limited Partnership invested in 0.03% or 102,643 shares.

Among 7 analysts covering Jack Henry (NASDAQ:JKHY), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. Jack Henry has $128 highest and $69 lowest target. $120.60’s average target is -1.21% below currents $122.08 stock price. Jack Henry had 17 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 16 by RBC Capital Markets. The company was maintained on Thursday, August 27 by RBC Capital Markets. The stock of Jack Henry & Associates, Inc. (NASDAQ:JKHY) has “Hold” rating given on Thursday, January 4 by RBC Capital Markets. The firm has “Neutral” rating by Robert W. Baird given on Tuesday, October 10. The rating was maintained by Robert W. Baird on Sunday, September 17 with “Hold”. On Tuesday, August 15 the stock rating was maintained by Oppenheimer with “Hold”. RBC Capital Markets maintained the shares of JKHY in report on Thursday, November 9 with “Hold” rating. On Wednesday, December 6 the stock rating was upgraded by Evercore to “In-Line”. Stephens maintained Jack Henry & Associates, Inc. (NASDAQ:JKHY) rating on Monday, February 5. Stephens has “Hold” rating and $118.0 target. RBC Capital Markets maintained the shares of JKHY in report on Wednesday, July 5 with “Hold” rating.

The stock increased 0.97% or $1.17 during the last trading session, reaching $122.08. About 364,615 shares traded or 10.32% up from the average. Jack Henry & Associates, Inc. (NASDAQ:JKHY) has risen 21.47% since February 17, 2017 and is uptrending. It has outperformed by 4.77% the S&P500.

Jack Henry & Associates, Inc. provides technology solutions and payment processing services primarily for financial services organizations in the United States. The company has market cap of $9.43 billion. The firm offers information and transaction processing solutions for banks ranging from community to multi-billion dollar institutions under the Jack Henry Banking brand; core data processing solutions for various credit unions under the Symitar brand; and specialized financial performance, imaging and payments processing, information security and risk management, retail delivery, and online and mobile solutions to financial institutions and corporate entities under the ProfitStars brand. It has a 27.64 P/E ratio. It also provides a suite of integrated applications required to process deposit, loan, and general ledger transactions, as well as to maintain centralized customer/member information; and complementary services and products that enable core bank and credit union clients to respond to evolving customer/member demands.

Since September 20, 2017, it had 0 insider purchases, and 2 insider sales for $2.30 million activity. WILLIAMS KEVIN D sold $2.03M worth of Jack Henry & Associates, Inc. (NASDAQ:JKHY) on Wednesday, September 20. $263,025 worth of Jack Henry & Associates, Inc. (NASDAQ:JKHY) was sold by Forbis Mark S on Wednesday, September 20.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 0.52, from 1.74 in 2017Q2. It dropped, as 13 investors sold Flexion Therapeutics, Inc. shares while 28 reduced holdings. 22 funds opened positions while 28 raised stakes. 26.01 million shares or 2.53% more from 25.36 million shares in 2017Q2 were reported. Alps Advisors Inc reported 0.01% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). New York State Common Retirement Fund stated it has 37,893 shares. Gam Ag reported 130,500 shares. Gagnon Securities Lc stated it has 1.25% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Goldman Sachs Gp Inc reported 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Natl Bank Of America Corp De reported 29,023 shares. Legal General Group Inc Public Ltd Llc holds 6,818 shares or 0% of its portfolio. Dupont reported 0.01% stake. Deutsche Savings Bank Ag invested in 0% or 27,283 shares. Macquarie Limited invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). State Of Wisconsin Investment Board holds 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 21,000 shares. Pictet Asset Mngmt Limited stated it has 0.04% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). 175,000 are owned by Ardsley Advisory Prns. 55,250 were reported by Scholtz And. Tpg Grp Incorporated (Sbs) Advsr accumulated 0.37% or 936,507 shares.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company has market cap of $870.57 million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. It currently has negative earnings.

Among 10 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 22 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Wednesday, October 4 by Northland Capital. The firm has “Buy” rating by RBC Capital Markets given on Monday, September 11. RBC Capital Markets maintained Flexion Therapeutics, Inc. (NASDAQ:FLXN) on Friday, July 7 with “Buy” rating. As per Tuesday, May 3, the company rating was reinitiated by Wells Fargo. The rating was maintained by BMO Capital Markets on Monday, October 9 with “Outperform”. Wells Fargo maintained Flexion Therapeutics, Inc. (NASDAQ:FLXN) on Monday, October 30 with “Buy” rating. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, October 24 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, June 12. The firm has “Outperform” rating given on Wednesday, June 29 by BMO Capital Markets. The firm has “Buy” rating by Needham given on Friday, September 15.

Leave a Reply

Your email address will not be published. Required fields are marked *